Skip to main content
OpenTrials

Clinical trial condition

Recurrent Lung Non-Small Cell Carcinoma

Explore clinical trials studying Recurrent Lung Non-Small Cell Carcinoma. Study availability and eligibility vary by location and protocol.

47 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Lung Non-Small Cell Carcinoma trial results

Active, not recruiting

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

NCT02496663

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
View all 15 locations
View Trial Details
Active, not recruiting

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

NCT04227028

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +17 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Northwestern University Chicago, Illinois, United States
  • Rush University Medical Center Chicago, Illinois, United States
View Trial Details
Active, not recruiting

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

NCT02503722

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada
View Trial Details
Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, not recruiting

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

NCT04250545

Conditions
Brain Diseases, Brain Neoplasms, Bronchial Neoplasms, +21 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • Keck Medicine of USC Koreatown Los Angeles, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View Trial Details
Active, not recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT05096663

Conditions
Advanced Lung Non-Small Cell Carcinoma, Bronchial Neoplasms, Carcinoma, Bronchogenic, +16 more
Locations
  • Veterans Administration Medical Center - Birmingham Birmingham, Alabama, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 350 locations
View Trial Details

Related conditions